نتایج جستجو برای: bevacizumab avastin

تعداد نتایج: 11361  

Journal: :بینا 0
حمید خوش نیت h khoshniyat شیراز- مرکز تحقیقات پوستچی حمیدرضا جهادی حسینی hr jahadi-hosseini شیراز- مرکز تحقیقات پوستچی محمود نجابت m nejabat شیراز- مرکز تحقیقات پوستچی کامران فاتحی k fatehi شیراز- مرکز تحقیقات پوستچی مهناز مصلایی m mosallaei شیراز- مرکز تحقیقات پوستچی محمد انصافداران m ensafdaran شیراز- مرکز تحقیقات پوستچی

purpose: to report subconjunctival injection of bevacizumab (avastin) for treatment of primary active pterygium. method: patients with primary active pterygia without other ocular disease, pregnancy or diabetes mellitus were enrolled. patients were randomly allocated into two groups to receive injection of avastin or placebo. patients were evaluated for changes in photophobia, conjunctival cong...

Journal: :Clinical advances in hematology & oncology : H&O 2014
Edith A Perez

Women with high-risk HER2-negative breast cancer do not benefit from the addition of bevacizumab (Avastin, Genentech) to standard chemotherapy, according to results from the Eastern Cooperative Oncology Group 5103 (E5103) trial. “Our results are quite similar to those reported previously for the BEATRICE and the BETH trials, which enrolled patients with HER2-positive disease,” said presenter Dr...

Journal: :Archivos de la Sociedad Española de Oftalmología 2008

2013
YUN FAN ZHIYU HUANG WEIMIN MAO

The safety of Avastin in lung cancer (SAiL) study is a multi-center, open-source, stand-alone study. Patients with untreated, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) were administered up to six cycles of chemotherapy combined with bevacizumab-humanized monoclonal antibodies, followed by maintenance therapy with bevacizumab until further progress...

2016
Aya Nakaya Takayasu Kurata Takashi Yokoi Shigeyoshi Iwamoto Yoshitaro Torii Yuichi Katashiba Makoto Ogata Madoka Hamada Masanori Kon Shosaku Nomura

Bevacizumab(Avastin(®) ), a humanized therapeutic monoclonal antibody that targets vascular endothelial growth factor, is widely used in cancer treatment. Patients who are treated with bevacizumab have an increased risk of developing systemic hypertension. However, the relationship between bevacizumab-induced hypertension and clinical outcome remains unclear. We aimed to evaluate the effect of ...

Journal: :Journal of glaucoma 2007
Shahin Yazdani Kamran Hendi Mohammad Pakravan

Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion w...

Journal: :Archivos de la Sociedad Espanola de Oftalmologia 2011
X Valldeperas R Bonilla M R Romano J de la Cámara

CASE REPORT A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C(3)F(8) and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) ...

2016
Lei Chen Xiaoyu Yang Da Luo Weichang Yu

Bevacizumab, a humanized monoclonal antibody (mAb) targeting to the vascular endothelial growth factor (VEGF), has been widely used in clinical practice for the treatment of multiple cancers. Bevacizumab was mostly produced by the mammalian cell expression system. We here reported the first plant-derived Bevacizumab by using transgenic rice callus as an alternative gene expression system. Codon...

Journal: Surgery and Trauma 2016

Introduction: Intravitreal Avastin (bevacizumab) injection is reportedly accompanied by ocular and systemic side-effects. Our enquiry assesses whether there are any differences between intraocular pressure (IOP) in baseline and on the day after injection in patients treated for retinal disease. Methods: In this experimental study, 82 eyes with retinal diseases that had indication for anti-VEGF...

Journal: :Archives of ophthalmology 2011
Hidetaka Yamaji Fumio Shiraga Chieko Shiragami Hiroyuki Nomoto Tomoyoshi Fujita Kouki Fukuda

B evacizumab (Avastin) is a full-length recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). It has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer. Intravitreous (IV) injection of bevacizumab, 1.25 mg/0.05 mL, has been studied in patients with age-related macular degeneration, macular edema ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید